Oramed Pharmaceuticals Inc.
ORMPNASDAQHealthcare● Active
$3.64
$-0.07(-1.89%)
Market Cap$148970935
P/E Ratio—
52W High$5.01
52W Low$1.98
Oramed Pharmaceuticals Inc. (ORMP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ORMP · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 19, 2026EPS Actual
-$0.16
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 19, 2026
After Market Close
✓ 2-Quarter EPS Beat Streak
ORMP reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$78.12
Rev. $1025.0B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$78.12
Rev. Est.$1025.0B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 14, 2026 | — | — | — | — | — | — |
| — Q2 FY2026 | May 19, 2026 | — | -$0.16 | — | — | — | — |
| ▲ Q1 FY2026 | Mar 26, 2026 | -$0.08 | -$0.06 | +25.0% | — | $0.00B | — |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.04 | $1.13 | +2925.0% | — | — | — |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$0.04 | -$0.05 | -25.0% | — | — | — |
| ▼ Q2 FY2025 | May 15, 2025 | -$0.03 | -$0.19 | -533.3% | $0.00B | — | — |
| ▲ Q1 FY2025 | Mar 27, 2025 | -$0.03 | $0.01 | +133.3% | — | — | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.00 | -$0.48 | -9695.9% | — | — | — |
Q3 FY2026
Aug 14, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 19, 2026
EPS Actual
-$0.16
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 26, 2026Beat
EPS Actual
-$0.06
EPS Est.
-$0.08
EPS Surpr.
+25.0%
Revenue
—
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
$1.13
EPS Est.
-$0.04
EPS Surpr.
+2925.0%
Revenue
—
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$0.05
EPS Est.
-$0.04
EPS Surpr.
-25.0%
Revenue
—
Q2 FY2025
May 15, 2025Miss
EPS Actual
-$0.19
EPS Est.
-$0.03
EPS Surpr.
-533.3%
Revenue
$0.00B
Q1 FY2025
Mar 27, 2025Beat
EPS Actual
$0.01
EPS Est.
-$0.03
EPS Surpr.
+133.3%
Revenue
—
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.48
EPS Est.
-$0.00
EPS Surpr.
-9695.9%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Q3 FY2025 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q2 FY2025 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q1 FY2025 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q4 FY2024 | $-0.05 | $-0.02 | $0.01 | 1 |
| Q3 FY2024 | $-0.01 | $0.01 | $0.01 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | May 19, 2026 | — | $4.29 | $4.33 | +0.93% |
| ▲ Q1 FY2026 | Mar 26, 2026 | +25.0% | $3.50 | $3.32 | -5.14% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +2925.0% | $2.47 | $2.40 | -2.83% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -25.0% | $2.12 | $2.12 | +0.00% |
| ▼ Q2 FY2025 | May 15, 2025 | -533.3% | $2.21 | $2.20 | -0.45% |
| ▲ Q1 FY2025 | Mar 27, 2025 | +133.3% | $2.36 | $2.30 | -2.54% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -9695.9% | $2.34 | $2.38 | +1.71% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +2500.0% | $2.36 | $2.24 | -5.08% |
Q2 FY2026+0.93%
Report Date
May 19, 2026
EPS Beat/Miss
—
Price Before
$4.29
Price After
$4.33
Q1 FY2026-5.14%
Report Date
Mar 26, 2026
EPS Beat/Miss
+25.0%
Price Before
$3.50
Price After
$3.32
Q4 FY2025-2.83%
Report Date
Nov 13, 2025
EPS Beat/Miss
+2925.0%
Price Before
$2.47
Price After
$2.40
Q3 FY2025+0.00%
Report Date
Aug 14, 2025
EPS Beat/Miss
-25.0%
Price Before
$2.12
Price After
$2.12
Q2 FY2025-0.45%
Report Date
May 15, 2025
EPS Beat/Miss
-533.3%
Price Before
$2.21
Price After
$2.20
Q1 FY2025-2.54%
Report Date
Mar 27, 2025
EPS Beat/Miss
+133.3%
Price Before
$2.36
Price After
$2.30
Q4 FY2024+1.71%
Report Date
Nov 7, 2024
EPS Beat/Miss
-9695.9%
Price Before
$2.34
Price After
$2.38
Q3 FY2024-5.08%
Report Date
Aug 14, 2024
EPS Beat/Miss
+2500.0%
Price Before
$2.36
Price After
$2.24
Avg Beat Reaction-3.90%
Avg Miss Reaction+0.42%
Beat Rate4 / 8 quarters
Largest Move-5.14% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ORMP ends December
Oramed Pharmaceuticals Inc. (ORMP) most recently reported earnings on May 19, 2026 for Q2 FY2026, posting EPS of $-0.16 (in line with the analyst consensus of —). ORMP has beaten EPS estimates for 2 consecutive quarters. The next ORMP earnings date is expected around September 1, 2026.
Each quarter, investors track ORMP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ORMP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ORMP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ORMP earnings · 4 questionsOramed Pharmaceuticals Inc.'s next earnings report is expected around September 1, 2026. ORMP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ORMP historically reports after market close (AMC).
ORMP earnings datewhen is ORMP earningsORMP next earnings datewhen does ORMP report earningsORMP earnings calendar
▸ Source: FMP · Oramed Pharmaceuticals Inc. SEC filings · US GAAP · Oramed Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026